Literature DB >> 28543949

Vernal keratoconjunctivitis treated with omalizumab: A case series.

Francesca Occasi1, Marzia Duse1, Marcella Nebbioso2, Giovanna De Castro1, Marco Di Fraia1, Giulia Capata1, Valeria Lollobrigida1, Anna Maria Zicari1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28543949     DOI： 10.1111/pai.12737

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN： 0905-6157            Impact factor:   6.377


× No keyword cloud information.
  6 in total

Review 1.  Emerging Therapeutics for Ocular Surface Disease.

Authors:  Leonard Bielory; Dovid Schoenberg
Journal:  Curr Allergy Asthma Rep       Date:  2019-02-28       Impact factor: 4.806

Review 2.  An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics.

Authors:  Roberto Bernardini; Gaia Toschi Vespasiani; Arianna Giannetti
Journal:  Medicina (Kaunas)       Date:  2022-04-29       Impact factor: 2.948

3.  Effects of omalizumab on allergic conjunctivitis.

Authors:  E Kırıkkaya; P Değirmenci
Journal:  Int Ophthalmol       Date:  2021-08-24       Impact factor: 2.031

Review 4.  Pediatric usage of Omalizumab: A promising one.

Authors:  Lin Yu; Huishan Zhang; Jianwei Pan; Leping Ye
Journal:  World Allergy Organ J       Date:  2021-12-11       Impact factor: 4.084

Review 5.  Vernal keratoconjunctivitis: state of art and update on treatment.

Authors:  Giulia Brindisi; Bianca Cinicola; Caterina Anania; Giovanna De Castro; Marcella Nebbioso; Michele Miraglia Del Giudice; Amelia Licari; Carlo Caffarelli; Maria De Filippo; Fabio Cardinale; Marzia Duse; Anna Maria Zicari
Journal:  Acta Biomed       Date:  2021-11-29

Review 6.  Vernal keratoconjunctivitis.

Authors:  Hampton Addis; Bennie H Jeng
Journal:  Clin Ophthalmol       Date:  2018-01-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.